Lilly's Obesity Pill Just Cleared Its Biggest European Hurdle
Eli Lilly's oral obesity pill Foundayo just scored a positive EMA recommendation, setting up a showdown with Novo Nordisk's oral Wegovy across Europe. Lilly is arriving second, but it's bringing a simpler dosing regimen, better head-to-head data, and a broader label to the fight.
The obesity drug war just moved from needles to pill bottles, and Europe is the new front line.
Eli Lilly's oral obesity drug Foundayo (orforglipron) just picked up a positive recommendation from the EMA's human medicines committee (CHMP), the panel that decides which drugs get the green light in Europe. That recommendation is essentially the last major checkpoint before the European Commission grants formal marketing authorization. And when that happens, Foundayo will become the second oral obesity pill cleared for sale across the EU.
The first? Novo Nordisk's oral Wegovy, which got its EU approval back in July.
So Lilly is playing catch-up. But that doesn't mean it's losing.
A Pill You Can Actually Take Like a Normal Person
Foundayo is a once-daily tablet, and its biggest selling point might be the simplest one: you can take it with or without food, at any time of day. That matters more than it sounds.
Novo's oral semaglutide (the active ingredient in oral Wegovy) requires patients to take it on an empty stomach with a specific amount of water, then wait before eating. It's not exactly a dealbreaker, but it's a hassle. Foundayo skips all of that. Pop a pill with your morning coffee, your lunch, or right before bed. Done.
For a drug that patients may take for years, convenience isn't a luxury. It's a retention strategy.
The Numbers: Good, Not Great, But Good Enough
Foundayo's weight-loss results won't blow anyone away if you're comparing them to injectable tirzepatide (Lilly's blockbuster Zepbound). But for an oral drug, they're competitive.
In the ATTAIN-1 trial, patients on the highest dose (36 mg) lost an average of 11.2% of their body weight over 72 weeks, compared to 2.1% for placebo. When researchers looked only at patients who stayed on the drug the whole time, that number climbed to 12.4%, translating to about 27 pounds.
More than half of patients on the top dose lost at least 10% of their body weight. About one in five lost 20% or more.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Those aren't injectable-level results (where top-tier drugs push past 20% average weight loss), but they're meaningful. Think of it this way: if injectable GLP-1s are a five-star restaurant, oral ones are a really solid neighborhood bistro. Most people would be thrilled with either.
The Head-to-Head That Matters
Lilly ran a direct comparison against Novo's oral semaglutide, and the results leaned decisively in Foundayo's favor. At the highest doses tested, Foundayo delivered 9.2% weight loss compared to 5.3% for oral semaglutide. That's roughly 74% more relative weight loss.
Now, caveats apply. These are trial averages, not guarantees. Real-world results will vary, and pricing and insurance coverage will matter just as much as efficacy for most patients. But when you're pitching doctors and payers on your pill versus the other guy's pill, a head-to-head win is a powerful talking point.
Europe should be a goldmine for obesity drugs. Prevalence is high, treatment rates are low, and the market is projected to balloon from roughly $1.9 billion in 2025 to $16.9 billion by 2035.
But "should be" is doing a lot of heavy lifting in that sentence.
The reality is that reimbursement across Europe is a patchwork quilt stitched together by bureaucrats who can't agree on anything. Germany, the EU's largest market, generally excludes obesity drugs from statutory insurance coverage. The UK offers limited NHS access, but many patients end up paying out of pocket. France is the outlier, covering obesity drugs at 65% (and often effectively 100% for patients with comorbidities).
Only about 2% of European and UK adults currently use GLP-1 drugs. That's roughly 9 to 10 million people, in a continent where Germany alone has roughly 16 to 17 million people living with obesity. The gap between prevalence and treatment is enormous, and it represents both the opportunity and the frustration for drugmakers.
Oral drugs could help crack that gap open. They're easier to prescribe, easier to take, and could eventually come at lower price points than injectables. Analysts expect a meaningful shift toward oral GLP-1s in Europe starting in 2027, which is conveniently when Lilly plans to actually launch Foundayo in the EU.
The Scoreboard: Novo Leads, Lilly Lurks
Let's be clear about where things stand. Novo Nordisk is winning the European regulatory race right now. Oral Wegovy got its EU approval in July 2026. Foundayo just got the CHMP nod in October and still needs the Commission's formal sign-off. Novo has a roughly three-month head start, and it's already planning European launches for late 2026.
Lilly, meanwhile, isn't expected to launch Foundayo in the EU until 2027. In the U.S., it's a different story: Foundayo received FDA approval back in April 2026 after a lightning-fast 50-day review. The drug is already on the market stateside and has captured over 30% of new U.S. patients starting on oral weight-loss drugs.
So Lilly has proven it can compete commercially. The question is whether being second to market in Europe actually matters that much.
Why Second Place Might Be Just Fine
Being second isn't always a disadvantage. Lilly has a broader recommended label in Europe: Foundayo covers both weight management and type 2 diabetes, while oral Wegovy's EU approval focuses on weight management. That diabetes indication gives Lilly access to a whole separate patient population and, critically, potentially friendlier reimbursement pathways in countries that cover diabetes drugs more generously than obesity drugs.
Then there's the convenience factor (no fasting, no water rules) and the head-to-head efficacy data. Lilly also brings massive commercial infrastructure; some analysts project Lilly's oral drug could capture 60% of the daily oral obesity segment by 2030, with Novo holding around 21%.
Injectables still account for the clear majority of new patient starts in obesity treatment. But the trajectory is clear: Novo's own CEO has suggested oral drugs could eventually make up half the global obesity drug market. The pie is getting bigger, and it's increasingly pill-shaped.
The Bottom Line
Foundayo's European green light is a formality waiting to happen. The CHMP positive opinion almost always leads to Commission approval. When it does, Lilly will have a competitive oral obesity drug on both sides of the Atlantic, armed with a simpler dosing regimen, strong head-to-head data, and a dual indication that Novo doesn't match.
The obesity drug market is no longer a two-horse injectable race. It's becoming a four-lane highway: injectable Wegovy, injectable Zepbound, oral Wegovy, and oral Foundayo. For the roughly 9 million Europeans already on GLP-1 drugs (and the tens of millions who aren't), more competition means more options, better access, and eventually, lower prices.
That's good news for patients. For Novo and Lilly, it's game on.
Funding & Financings5 min read
RNAi's Biggest Problem Just Got a $200 Million Bet
City Therapeutics just raised $200 million in an upsized IPO to crack RNAi's hardest problem: getting gene-silencing drugs to work outside the liver. With a team of Alnylam alumni and nearly half a billion in total funding, they're making the biggest bet yet on extrahepatic delivery.
